CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation

CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation

Today, pharmacogenetic tests are commonly used to improve the efficacy and safety of antipsychotic (AP) treatment. However, the economic aspects of their implementation in the psychiatry clinic routine are not well studied.Aim.To evaluate the pharmacoeconomic benefits of CYP2D6 polymorphisms genotyp...

Full description

Bibliographic Details
Main Authors:	A. A. Kurylev, B. V. Andreev, A. S. Kolbin, O. V. Limankin
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2018-05-01
Series:	Фармакоэкономика
Subjects:	cyp2d6 polymorphisms antipsychotics pharmacoeconomics
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/226

Similar Items

Systematic review of pharmacoeconomic models for schizophrenia
by: Junwen Zhou, et al.
Published: (2018-01-01)

Efficacy and safety of antipsychotics in adolescents with an acute psychotic episode in relation to the activity of CYP3A and CYP2D6 isoenzymes
by: D. V. Ivashchenko, et al.
Published: (2020-12-01)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
by: Junwen Zhou, et al.
Published: (2019-01-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2022-12-01)

Pharmacoeconomic analysis of Flemoclav Solutab® use in adult patients with acute sinusitis in routine outpatient clinical practice in Russia
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population
by: Sagheer Ahmed, et al.
Published: (2021-03-01)

CYP2D6 GENETIC POLYMORPHISM AND EXTRAPYRAMIDAL SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS
by: Vita Dolžan, et al.
Published: (2002-07-01)

POLYMORPHISM OF CYTOCHROME P450 2A6 (CYP2A6*1 AND CYP2A6*4) AMONG JAVANESE INDONESIAN SMOKER AND NON SMOKER
by: Christine Patramurti, et al.
Published: (2015-01-01)

Genetic polymorphism of CYP2D6 gene among Egyptian hypertensive cases
by: Ahmed A.A. Ali, et al.
Published: (2013-08-01)

PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA
by: A. V. Pavlysh, et al.
Published: (2015-03-01)

Pharmacoeconomic effectiveness of phytotherapy in complex treatment of pyelonephritis
by: V. V. Ivanov, et al.
Published: (2015-04-01)

Pharmacoeconomics of Bronchial Asthma
by: Ivanova Zlatina I., et al.
Published: (2019-06-01)

Pharmacoeconomic analysis of denosumab in patients with breast cancer and bone metastases
by: A. S. Kolbin, et al.
Published: (2018-05-01)

PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
by: A. S. Kolbin, et al.
Published: (2015-03-01)

CYP2A6 and CYP2E1 polymorphisms in a Brazilian population living in Rio de Janeiro
by: Rossini A., et al.
Published: (2006-01-01)

CYP2D6 Genotype-Based Dose Recommendations for Risperidone in Asian People
by: Yuanxia Cui, et al.
Published: (2020-08-01)

CYP2D6 Genetic Variation and Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis
by: Yanisa Wannasuphoprasit, et al.
Published: (2022-02-01)

THE FEATURES OF METHODOLOGY FOR PHARMACOECONOMICS ANALYSIS OF VACCINATION
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC STUDIES OF ANTIHYPERTENSIVE TREATMENT IN RUSSIA. Analytical Review
by: T. S. Romanenko, et al.
Published: (2015-09-01)

Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population
by: Nada Ezzeldin, et al.
Published: (2018-05-01)

Pharmacoeconomic particulars of ovaries cancer’s treatment
by: V N Zhurman, et al.
Published: (2015-06-01)

Pharmacoeconomic aspects of COVID-19 treatment
by: I. V. Rogova, et al.
Published: (2021-10-01)

PHARMACOECONOMIC ANALYSIS OF MARKET OF BIOLOGICALLY ACTIVE ADDITIVES MERCHANDIZED IN PHARMACY ORGANIZATIONS
by: O. V. Belousova, et al.
Published: (2015-12-01)

Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-08-01)

Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients
by: Sze Wa Chan, et al.
Published: (2021-09-01)

Current Situation and Prospect of Pharmacoeconomic Evaluation of Hemophilia in China
by: LI Shunping, et al.
Published: (2022-10-01)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
by: Mirza Bojić, et al.
Published: (2019-09-01)

Analysis of effectiveness criteria in pharmacoeconomic studies of hypoglycemic drugs proposed for inclusion into the essential drug list in 2014-2016 in Russia
by: A. A. Mosikyan, et al.
Published: (2018-05-01)

Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital
by: A. S. Kolbin, et al.
Published: (2015-03-01)

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice
by: Qamar Shubbar, et al.
Published: (2024-02-01)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
by: Werner Schroth, et al.
Published: (2017-08-01)

PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION
by: V. A. Chibilyaev, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of the use of movalis (meloxicam) in patients with nonspecific back pain
by: O. N. Gerasimova, et al.
Published: (2011-12-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-05-01)

Pharmacoeconomic analysis of classic and alternative eradication therapy regimens for Helicobacter pylori
by: A. M. Veliyev, et al.
Published: (2019-05-01)

Pharmacoeconomics in Africa: needs, prospect and challenges
by: Temitope Ben-Ajepe, et al.
Published: (2021-12-01)

Outlook of Pharmacoeconomics and its status in Nepal
by: Sabita Paudel
Published: (2018-03-01)

Role of <it>CYP2E1 </it>genotypes in susceptibility to colorectal cancer in the Kashmiri population
by: Sameer A, et al.
Published: (2011-10-01)

Pharmacoeconomics as an instrument of clinical pharmacology for optimization of pharmacotherapy
by: Reshetko O.V., et al.
Published: (2015-09-01)